• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.

Principal Investigator(s)


Lucy Clayton




Traumatic brain injury (TBI) is a major cause of mortality and morbidity. Many survivors suffer from concentration deficit, fatigue, depression and low resistance to effort. These symptoms affect their quality of life, their functional level and have a significant impact on primary health care resources utilization. Several of these symptoms could be attributable to hormonal deficits. In fact, pituitary disorders are an often neglected side effect of TBI. Nonetheless, studies published to date have not adequately evaluated the clinical impact of pituitary disorders nor their risk factors in the context of TBI.

The main objectives of this study will be to evaluate the feasibility of conducting a large multicenter prospective observational cohort study. We will evaluate protocol adherence and we will estimate the recruitment rate at each participating centre.

This study, conducted in 5 trauma centres across Canada, is a critical step in an innovative research program on pituitary disorders. This study will have a significant impact on health care in Canada. Indeed, if we demonstrate that pituitary disorders affect the neurological prognostic, functional status, quality of life or depressive symptoms of patients, our results will justify the implementation of a systematic screening strategy to detect these disorders in patients suffering from TBI.

These results would then also justify the conduct of randomized clinical trials to evaluate the relevance of initiating hormonal replacement therapy. On the other hand, if we show that pituitary disorders and prognosis are not linked, our results will prevent unnecessary, costly screening and prevent potentially harmful hormonal replacement therapy in this vulnerable population.

This study is funded by a grant from the Canadian Institute of health Research and by a grant from the Fonds de la Recherche du Québec - Santé.

Participating Centers

CHU de Québec –Université Laval, Hôpital de l’Enfant-Jésus (Québec City, Québec) ; Hôpital du Sacré-Cœur de Montréal (Montréal, Québec) ; Centre Hospitalier Universitaire de Sherbrooke (Sherbrooke, Québec) ; The Ottawa Hospital (Ottawa, Ontario); Sunnybrook Health Sciences Centre (Toronto, Ontario); Nova Scotia Health Autority (Halifax, Nova Scotia).